Chronic obstructive pulmonary disease (
COPD) is characterized by an airways
inflammation and by an enhanced generation of
reactive oxygen species. The aim of our study was to assess the
inflammation and the oxidative stress in airways of
COPD patients with acute exacerbation of disease and in stability. Furthermore, we investigated the anti-inflammatory and
antioxidant effects of 6 months treatment with
carbocysteine lysine salt monohydrate (
SCMC-Lys) in
COPD. We studied 30 mild acute
COPD, 10 mild stable
COPD and 15 healthy subjects.
8-isoprostane and Interleukine-6 were measured in their breath condensate through immunoassay. Significantly higher concentrations of exhaled
8-isoprostane and Interleukine-6 were found in acute
COPD patients compared to stable
COPD and healthy controls (21.8+/-5.1 vs. 13.2+/-2.0 vs. 4.7+/-1.8 pg/ml and 7.4+/-0.9 vs. 5.8+/-0.2 vs. 2.7+/-0.6 pg/ml, p<0.0001).
COPD patients treated with
SCMC-Lys showed a marked reduction of exhaled
8-isoprostane and Interleukine-6 (8.9+/-1.5 and 4.6+/-0.8 pg/ml, p<0.0001). These findings suggest that there is an increase of
8-isoprostane and Interleukine-6 concentrations in the breath condensate of
COPD patients compared to healthy controls especially during acute exacerbations of the disease. Moreover, we showed an anti-inflammatory and
antioxidant effect of short-term administration of
SCMC-Lys in
COPD, suggesting the importance of a further placebo-controlled study that should evaluate the effects of this
drug.